Cimerli (ranibizumab-eqrn) - Amneal, Formycon, Coherus Oncology, Teva, Bio Usawa, Bioeq AG
Otulfi (ustekinumab-aauz) - Formycon, Fresenius Kabi
https://www.formycon.com/en/blog/press-release/formycon-publishes-nine-month-results-and-confirms-guidance-pipeline-progress-and-strong-partnerships-drive-fiscal-year-2025/
 
Nov 13, 2025
 
Next